PT - JOURNAL ARTICLE AU - Lind, Margaret L. AU - Robertson, Alexander James AU - Silva, Julio AU - Warner, Frederick AU - Coppi, Andreas C. AU - Price, Nathan AU - Duckwall, Chelsea AU - Sosensky, Peri AU - Giuseppe, Erendira C. Di AU - Borg, Ryan AU - Fofana, Mariam O AU - Ranzani, Otavio T. AU - Dean, Natalie E. AU - Andrews, Jason R. AU - Croda, Julio AU - Iwasaski, Akiko AU - Cummings, Derek A.T. AU - Ko, Albert I. AU - Hitchings, Matt DT AU - Schulz, Wade L. TI - Effectiveness of Primary and Booster COVID-19 mRNA Vaccination against Infection Caused by the SARS-CoV-2 Omicron Variant in People with a Prior SARS-CoV-2 Infection AID - 10.1101/2022.04.19.22274056 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.19.22274056 4099 - http://medrxiv.org/content/early/2022/04/21/2022.04.19.22274056.short 4100 - http://medrxiv.org/content/early/2022/04/21/2022.04.19.22274056.full AB - Importance The benefit of primary and booster vaccination in people who experienced prior SARS-CoV-2 infection remains unclear.Objective To estimate the effectiveness of a primary (two-dose) and booster (third dose) vaccination against Omicron infection among previously infection people.Design Test-negative case-control study.Setting Yale New Haven Health System facilities serving southern Connecticut communities.Participants Vaccine eligible people who received SARS-CoV-2 RT-PCR testing between November 1, 2021, and January 31, 2022.Exposure COVID-19 mRNA primary and booster vaccination.Main Outcomes and Measures We conducted two analyses, each with an outcome of Omicron BA.1 variant infection (S-gene target failure defined) and each stratified by prior SARS-CoV-2 infection status. We estimated the effectiveness of primary vaccination during the period before and during booster eligibility (14-149 and ≥150 days, respectively, after 2nd dose) and of booster vaccination (≥14 days after booster dose). To test whether booster vaccination reduced the risk of infection beyond that of the primary series, we compared the odds among boosted and booster eligible people.Results Overall, 10,676 cases and 119,397 controls were included (median age: cases: 35 years, controls: 39 years). Among cases and controls, 6.1% and 7.8% had a prior infection. The effectiveness of primary vaccination 14-149 days after 2nd dose was 36.1% (95% CI, 7.1-56.1%) and 28.5% (95% CI, 20.0-36.2%) for people with and without prior infection, respectively. The effectiveness of booster vaccination was 45.8% (95% CI, 20.0-63.2%) and 56.9% (95% CI, 52.1-61.2%) in people with and without prior infection, respectively. The odds ratio comparing boosted and booster eligible people with prior infection was 0.83 (95% CI, 0.56-1.23), whereas the odds ratio comparing boosted and booster eligible people without prior infection was 0.51 (95% CI, 0.46-0.56).Conclusions and Relevance Primary vaccination provided significant but limited protection against Omicron BA.1 infection among people with and without prior infection. While booster vaccination was associated with additional protection in people without prior infection, it was not associated with additional protection among people with prior infection. These findings support primary vaccination in people regardless of prior infection status but suggest that infection history should be considered when evaluating the need for booster vaccination.Competing Interest StatementA.I.K serves as an expert panel member for Reckitt Global Hygiene Institute, scientific advisory board member for Revelar Biotherapeutics and a consultant for Tata Medical and Diagnostics and Regeneron Pharmaceuticals, and has received grants from Merck, Regeneron Pharmaceuticals and Tata Medical and Diagnostics for research related to COVID-19. W.L.S. was an investigator for a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; is a technical consultant to Hugo Health, a personal health information platform, and co-founder of Refactor Health, an AI-augmented data management platform for healthcare; and has received grants from Merck and Regeneron Pharmaceutical for research related to COVID-19. Other authors declare no conflict of interest.Funding StatementFunding for the Studying COVID-19 Outcomes after SARS-CoV-2 Infection and Vaccination (SUCCESS) Study was provided by the Beatrice Kleinberg Neuwirth and Sendas Family Funds, Merck and Co through their Merck Investigator Studies Program, and the Yale Schools of Public Health and Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Yale Institutional Review Board (ID# 2000030222).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study belongs to Yale University. Qualified researchers may submit a data share request for de-identified patient level data by contacting the corresponding author with a detailed description of the research question.